Abstract: Pharmaceutically active substances are administered in aerosol form by applying to a mucosal surface of the body a composition comprising a medically effective amount of a pharmaceutically active substance, a biocompatible amphiphilac steroid and a bicompatible (hydro/fluoro)carbon propellant.

Abstract: Non-dusty water-dispersible mancozeb granules (90%>100 micron diameter) are produced by a new process characterized by spray drying an aqueous slurry of .gtoreq.60% solids consisting of maneb or maneb dihydrate (5 microns, 50% 2-5 microns), a water soluble zinc salt and other formulation adjuvants.

Abstract: The invention involves a method for making uniformly sized particles from solid compounds. First, a suitable solid compound is dissolved in a suitable solvent. Then, a precipitating liquid is infused, precipitating non-aggregated particles with substantially uniform mean diameter. The particles are then separated from the solvent. Depending on the solid compound and the desired particle size, the parameters of temperature, ratio of non-solvent to solvent, infusion rate, stir rate, and volume can be varied according to the invention. The precipitating liquid may be aqueous or non-aqueous, depending upon the relative solubility of the compound and the desired suspending vehicle.

Abstract: A process for preparing sucrose fatty acid esters by reacting sucrose and a fatty acid alkyl ester in an aqueous reaction system in the presence of a catalyst, adding water to the reaction mixture to dissolve it, adjusting the reaction mixture to a neutral ph region, adding a neutral salt to the solution to precipitate the sucrose fatty acid esters, separating and washing the precipitate with an acidic water, and subjecting the washing liquid to ultrafiltration. The precipitate washed with the acidic water is spray-dried in the form of an aqueous slurry to give a dry powder of the sucrose esters having low HLB, and the concentrate obtained by ultrafiltration is spray-dried to form a dry powder of the sucrose esters having high HLB, and the liquid obtained by separating the precipitate is contacted with a reverse osmosis membrane to recover sucrose. According to the invention, purifed sucrose fatty acid esters can be obtained without using an organic solvent, while sucrose can be recovered in high yield.

Abstract: Riboflavin produced by a microbial method is prepared in the form of free-flowing, non-dusting, spray-dried granules or microgranules as a feed additive by removing water from the mixture discharged from microbial fermentation for the preparation of riboflavin, wherein the mixture is subjected to(a) a fluidized-bed spray-drying process(b) a one-material spray-drying process or(c) a disk spray-drying process without significant amounts of binders being added to the discharged fermentation mixture.

Abstract: Active ingredients useful in chewable articles of commerce are physically encased in non-porous, chewable, particles of elastomer and such particles are then incorporated in the articles of commerce. During mastication of the chewable article of commerce the active ingredient is released from the elastomer particles over a prolonged period of time. The active ingredients would include flavorants, intense sweeteners, colorants, medicaments, effervescent agents and tobacco.

Abstract: An antihyperlipidemic pharmaceutical or dietary supplement composition for oral use consisting essentially of a combination of niacin and guar gum, and a method of lowering cholesterol levels with such oral pharmaceutical composition, or by the simultaneous oral administration of the active ingredients thereof, which eliminates the usual undesirable flushing and itching side effects of niacin while effectively lowering cholesterol levels, especially LDL cholesterol levels, is disclosed.

Abstract: A composition for external application comprising kojic acid or a kojic acid derivative is characterized by formulating 4-(1,1-dimethylethyl)-4'-methoxydibenzoylmethan therein. The composition has the improved effects of inhibiting the formation of erythema and pigmentation caused by exposure to ultraviolet rays, preventing stains or freckles due to sunburn and preventing coloration after application, thus providing excellent compositions for external application as cosmetics, topical skin agents, etc.

Abstract: A chewable aspirin and buffering material tablet and method for producing same is disclosed herein. In a single dosage form the aspirin and buffering materials are integrally dispersed and bound in a fatty material of chocolate, synthetic chocolate or hydrogenated tallow. The tablet is for gastrointestinal applications and is especially adopted for use with animals, particularly dogs, and can be molded into a variety of shapes including that of a miniature dog bone.

Abstract: Microspheres, prepared by solvent removal from an oil-in-water emulsion using carboxylic acid salt surfactant, e.g., sodium oleate as the emulsifier.

Abstract: A cosmetic composition for the treatment of the hair and skin comprises at least 5 weight percent of pulverized particles of at least one plant. The particles have a granulometry lower than 125 microns. The compositions also includes a cohesion agent in an amount to maintain the homogeneity of the composition.

Abstract: A composition for effectively treating dandruff, seborrheic dermatitis and scalp psoriasis comprising a combination of essential ingredients consisting of microfine particles of a clay mineral containing adsorbed magnesium, water, ethanol, sodium chloride and, optionally, minor amounts of glycerin and precipitated sulfur. The effectiveness of the method in treating such scalp diseases by topical application to the scalp epidermis is predicated on the capacity of the composition to release and deliver magnesium cations and hydroxyl anions to the causative sites and return the associated pathological cells to a normal morphology.

Abstract: Formulae, means, and methods for the sublingual ingestion of natural Progesterone comprising milling and blending natural Progesterone such that it can be absorbed by the sublingual mucosae of a patient and applying it to said sublingual mucosae in a form which permits such absorption.

Abstract: A talc-base body powder composition having an unique composition of desirable characteristics including moisture absorbency, anti-ammonia, anti-bacterial and anti-fungal effects making it specially useful for infant skin care purposes consisting essentially of talc, cornstarch, calcium undeclyenate and citric or ascorbic acid in critical proportions.

Abstract: A deodorant composition comprising (A) an acidic phosphoric acid compound and (B) a copper compound and as desired, (C) a reducing agent, and a deodorant composite material comprising a substrate and the deodorant composition included therein.

Abstract: Novel surface-active, storage-stable compositons well adopted for the formulation of a variety of active agents, e.g., biocides, and the conversion thereof into stable, hmogenous liquid suspensions, are comprised of at least one first polyolefinic copolymeric surface-active agent (a) and at least one second mixed sulfate and/or phosphate ester surface-active agent (b).

Abstract: A method and a composition for accumulating and the binding of food fats in an animal body gastrointestinal tract. The method and composition rely upon non-biodegradable collagen particles, such as microspheres, having a size of at least two microns and a fat receptor, such as bile, capable of having food fat adhered thereto on the surface of the particles. These particles are sufficiently large so that they do not pass through the surface mucosa of the gastrointestinal tract and permit the particles with the food fat to pass through the gastrointestinal tract and out of the body through animal excretion.

Abstract: The present invention relates to an ingestible aggregate comprising a pre-swelled substantially anhydrous hydrocolloid and a substrate. More particularly this invention relates to an aggregate having as a substrate a dietary fiber and/or drug wherein the composition can be administered in a therapeutically effective amount. Hydrocolloids useful include natural and modified gums, celluloses, modified celluloses, pectins, mucillages, modified starches, noncellulose polysaccharides, algal polysaccharides and mixtures thereof. The aggregate should be in the size range of about 4 to about 70 U.S. mesh. The unpleasant taste and mouthfeel of the fiber and/or drug is effectively masked and substantial hydration is delayed until the composition reaches the stomach. The compositions are substantially more platable, devoid of graininess, bitterness or fibrous texture. The pleasant taste of the composition encourages patient compliance with their fiber or drug therapy.

Abstract: The invention relates to a biocidal fine powder with increased biocidal activity and an agricultural suspension containing the biocidal fine powder and an adjuvant selected from the group consisting of polyoxyalkylene-type nonionic surface active agents and polyoxyalkylene alkyl or alkylaryl ether phosphates or their salts.

Abstract: 5-Amino or substituted amino 1,2,3-triazoles are disclosed as a new class of antiproliferative agents useful in the treating and managing of psoriasis, inflammatory bowel syndrome, cutaneous leishmanilisis and certain types of cancer.

Abstract: The present invention relates to an ingestible aggregate comprising a pre-swelled substantially anhydrous hydrocolloid and a substrate. More particularly this invention relates to an aggregate having as a substrate a dietary fiber and/or drug wherein the composition can be administered in a therapeutically effective amount. Hydrocolloids useful include natural and modified gums, celluloses, modified celluloses, pectins, mucillages, modified starches, noncellulose polysaccharides, algal polysaccharides and mixtures thereof. The aggregate should be in the size range of about 4 to about 70 U.S. mesh. The unpleasant taste and mouthfeel of the fiber and/or drug is effectively masked and substantial hydration is delayed until the composition reaches the stomach. The compositions are substantially more palatable, devoid of graininess, bitterness or fibrous texture. The pleasant taste of the composition encourages patient compliance with their fiber or drug therapy.

Abstract: A facial cosmetic liquid contains a coloring phase containing crystalline mineral silica and coloring material; a major water phase containing water, an emulsifying component and a thickening component; and a minor oil phase containing emolient oils and an emulsifying component.

Abstract: A gel formation for oral administration having improved palatability comprising an effective hypocholesterolaemic amount of a uniform gelled dispersion of(a) between about 8 and about 20 percent by weight of a particulate, pharmaceutically acceptable, sparingly crosslinked non-digestible quaternary ammonium substituted polysytrene anion exchange resin having an average particle size below about 100 microns;(b) between about 4 and about 16 percent by weight of a pharmaceutically acceptable gelatin;(c) between about 0.015 and about 10 percent by weight of a natural or synthetic pharmaceutically acceptable sweetener;(d) between about 0.05 and about 2 percent by weight of a pharmaceutically acceptable organic acidulent;(e) between about 0.05 and about 5 percent by weight of one or more pharmaceutically acceptable flavoring or coloring agents or mixtures thereof; and(f) the remainder water.

Abstract: The invention involves a method for making uniformly sized particles from water-insoluble drugs or other organic compounds. First, a suitable solid organic compound is dissolved in an organic solvent, and the solution can be diluted with a non-solvent. Then, an aqueous precipitating liquid is infused, precipitating non-aggregated particles with substantially uniform mean diameter. The particles are then separated from the organic solvent. Depending on the organic compound and the desired particle size, the parameters of temperature, ratio of non-solvent to organic solvent, infusion rate, stir rate, and volume can be varied according to the invention.

Abstract: Process for the preparation of binder-free granules which can be compressed to give solid medicament forms, which consists in initially placing a predetermined amount of celiprolol hydrochloride, over 50% of which have a particle size below 40 .mu.m and not more than 10% have a particle size above 100 .mu.m, in a fluidized bed granulator, forming a fluidized bed by passing in additional air at a temperature not higher than 30.degree. C. and, by spraying distilled water into the fluidized bed preparing free-flowing granules having a water content of 20-40% by weight, less than 10% of which have a particle size below 63 .mu.m, and drying these granules at temperatures from 30.degree. to 60.degree. C. after they have been discharged, and the use thereof.

Abstract: A ground mixture of a poorly soluble crystalline drug and an adsorbent is remarkably improved in the rates of dissolution and adsorption of the drug.

Abstract: The present invention relates to medicaments with a high degree of dissolution rate and solubility. These medicaments are characterized in that they are in amorphous form produced by spraying in the presence of a stabilizer and of an agent inhibiting the formation of crystals.

Abstract: A dry pesticidal composition of a toxicant having a melting point in a range of from 0.degree. C. to 65.degree. C. (the said range of melting point applies also to the melting point of a mixure of toxicants) containing a hydrocarbon represented by the formula, ##STR1## wherein X.sub.1, X.sub.2, Y.sub.1, Y.sub.2, Z.sub.1 and Z.sub.2, which may be the same or different represent a hydrogen atom or an alkyl group having 2 or less carbon atom, R.sub.1 and R.sub.2, which may be the same or different, represent a hydrogen atom or a methyl group, and n represents 0 or 1.

Abstract: It has been found that certain derivatives of poly(diallylmethylamine) are therapeutically effective serum cholesterol lowering agents.

Abstract: The present invention relates to an ingestible aggregate comprising a pre-swelled substantially anhydrous hydrocolloid and a substrate. More particularly this invention relates to an aggregate having as a substrate a dietary fiber and/or drug wherein the composition can be administered in a therapeutically effective amount. Hydrocolloids useful include natural and modified gums, celluloses, modified celluloses, pectins, mucillages, modified starches, noncellulose polysaccharides, algal polysaccharides and mixtures thereof. The aggregate should be in the size range of about 4 to about 70 U.S. mesh. The unpleasant taste and mouthfeel of the fiber and/or drug is effectively masked and substantial hydration is delayed until the compositions reaches the stomach. The compositions are substantially more palatable, devoid of grainless, bitterness or fibrous texture. The pleasant taste of the composition encourages patient compliance with their fiber or drug therapy.

Abstract: Inert cross-linked copolymer able to absorb and then progressively release a pharmaceutically active substance, wherein it is constituted by a powder of a cross-linked copolymer comprising30 to 80% by weight of monounsaturated alkyl acrylate and/or methacrylate;5 to 68% by weight of acrylic and/or methacrylic acid; and2 to 15% by weight of bifunctional or trifunctional acrylate and/or methacrylate.A mixture of monounsaturated alkyl acrylate and/or methacrylate, acrylic and/or methacrylic acid, and bifunctional or trifunctional acrylate and/or methacrylate monomers is polymerized in accordance with a free radical polymerization mechanism.The support is used for the preparation of a delayed action or release medicament.

Abstract: Compounds of the formula I ##STR1## where the individual radicals R are identical or different and are each hydrogen, an alkali metal, or ammonium which is unsubstituted or substituted by organic radicals, or are each C.sub.1 -C.sub.20 -alkyl or a polyoxyethylene radical which contains from 1 to 10 ethylene oxide units and whose terminal OH group may be etherified by an alcohol of 1 to 3 carbon atoms, are used as sun screen agents.

Abstract: A pharmaceutical composition comprising a freely flowable powder, the powder comprising a porous, high absorption silica or silicate having absorbed therein at least 10% by volume of a liquid, pharmaceutically active composition, based on the weight of powder plus liquid, provided that when the liquid pharmaceutically active composition is a corticoid solution the silica or silicate has a mean particle size of at least 10 .mu.m in diameter.

Abstract: Therapeutic compositions are composed of four plant extracts: ginsenoside, tetramethyl pyrazine, astragalan and atractylol. Pharmaceutical dosage units are prepared by conventional means with specific weight ranges and proportions of each of the four ingredients. The pharmaceutical dosage units are highly effective in treating cerebral vascular disease and the sequelae thereof. The dosage units are also useful for bolstering immunofunction in healthy and diseased patients.

Abstract: A nematocide comprises S-methyl-N,N-di-C.sub.1-2 alkyl thiolcarbamate as an active ingredient.

Abstract: A method of formulating a synthetic drug for use in animal feed, for the purpose of reducing carry-over of the synthetic drug to subsequent lots of animal feed in the feed mill.

Abstract: A compressed powder formulation which consists essentially of an organophilic clay and at least one topical agent. The formulation maintains its physical integrity upon handling thereby permitting the preparation of the formulation in the form of self-supporting sticks and exhibits an acceptable level of payout. Additionally, the formulation retains an acceptable level of payout even when contacted with water. A process of making the formulation by compressing a powderous mixture is also set forth.

Abstract: A process for the preparation of solid pharmaceutical products, wherein, in a first step, spherical single crystals of a pharmaceutical active compound or assistant are prepared by agitating a saturated aqueous, organic or organic-aqueous solution in high speed stirred crystallizers or draft-tube crystallizers at 50-500 revolutions per minute and seeding the solution with finely ground seed crystals of particle size less than 100 .mu.m, while ensuring that at the time of addition of the seed crystals and during the growth thereof the solution is at all times only minimally supersaturated, this being achieved by slow cooling at a rate of not more than 50 K/h or corresponding slow evaporation of the solution, and in a second step the resulting spherical single crystals with diameters of 0.1-3 mm, preferably 0.5-2 mm, are separated from the solution, dried at 40.degree.-200.degree. C.

Abstract: The present invention relates to a new inert matrix having adjustable porosity and hardness.This matrix comprises polycaprolactone having an average molecular weight of between 2000 and 70,000, which is in the form of agglomerated grains having an average diameter of between 50 and 500 .mu.m and has a degree of crystallinity of at least 75%. The invention relates to the method for the preparation of a porous galenic form by means of the said matrix.

Abstract: What is provided by this invention is a powdery pharmaceutical composition for nasal administration comprising physiologically active polypeptide or its derivative such as calcitonin, insulin, etc. and a water-absorbing and water-insoluble base. The pharmaceutical composition allows polypeptide or its derivative to be efficiently absorbed through the nasal macous membrane when it is nasally administered.

Abstract: There is disclosed a granular composition having particles of average particle size as determined by sieving in the range 70 to 500 microns, the said particles comprising up to 55% of active ingredient e.g. ferrous sulphate having primary particles the maximum dimension (A) of which as determined by microscopy is less than 50 microns and a particulate water soluble extender e.g. lactose having an average particle size (B) as determined by sieving in excess of 50 microns, the particles of active ingredient and water soluble extender being held in self-supporting spaced relationship by a water insoluble polymer film matrix e.g. of a polyacrylate polymer, providing the balance of the weight of the particle and being less than 50% by weight of the particle.The invention also extends to a blend convertible by pressure alone to a substantially continuous three-dimensional porous matrix substantially devoid of separate resin particles, of active ingredient/water soluble extender/resin particles, e.g.

Abstract: Inert cross-linked copolymer able to absorb and then progressively release a pharmaceutically active substance, wherein it is constituted by a powder of a cross-linked copolymer comprising30 to 80% by weight of monounsaturated alkyl acrylate and/or methacrylate;5 to 68% by weight of acrylic and/or methacrylic acid; and2 to 15% by weight of bifunctional or trifunctional acrylate and/or methacrylate polymerized in accordance with free radical polymerization mechanisms.

Abstract: There is described a finely divided inhalation drug, e.g. sodium cromoglycate, comprising a therapeutically effective proportion of individual particles capable of penetrating deep into the lung, characterized in that a bulk of the particles which is both unagglomerated and unmixed with a coarse carrier, is sufficiently free flowing to be filled into capsules on an automatic filling machine and to empty from an opened capsule in an inhalation device. A number of the individual drug particles have a spherical, collapsed spherical or ring doughnut shape.There is also described a method of making the fine particles and pharmaceutical formulations containing them.

Abstract: Methylsulfonylmethane (MSM) is useful as a tableting and granulating aid for pharmaceutically active agents, especially those which are unstable in the presence of moisture, mixtures therewith being or formable into free-flowing powders or granules which are readily compressible into tablets of improved properties. A preferred method of forming such powders or granules involves mixing the pharmaceutically active agent under substantially anhydrous conditions with molten MSM or with particulate solid MSM at its softening point, cooling the resultant mixture and, when the MSM was molten, forming the solidified melt into granules or a free flowing powder and thereafter, if desired, compressing the powder or granules into tablets.

Abstract: A controlled release agglomerated carrier for pesticides and the like comprised of preselected portions of the pith, fine and coarse chaff and woody ring portions of a corncob which, when combined in varying ratios, define an overall release rate for the carrier and/or act as a bait for the targeted species.

Abstract: Described is the 4-(2-bornyloxy)-2-butyn-1-ol of our invention defined according to the structure: ##STR1## as well as methods for augmenting or enhancing the aroma of consumable materials including perfumes, colognes and perfumed articles by adding thereto an aroma augmenting or enhancing quantity of the 4-(2-bornyloxy)-2-butyn-1-ol of our invention.

Abstract: Rapid dissolving uniform compositions of low water solubility drugs are formed from a dry mixture of the drug having a reduced particle size in combination with properly selected and sized excipients including microcrystalline cellulose, dibasic calcium phosphate, starches and a lubricant.